Abstract
Acinetobacter, an important nosocomial pathogen, is capable of causing infectious outbreaks in critically ill patients which results into high morbidity and mortality worldwide. It is rated among top seven pathogens that disturb the health care delivery system. The situation has become complicated due to the organism’s capability to acquire diverse resistance mechanisms. This has resulted in the emergence of multidrug resistant and pan-drug resistant strains. A total of 100 clinical isolates of Acinetobacter spp. were evaluated against five β-lactam – β-lactamase inhibitor combinations by modified Kirby Bauer disc diffusion method using Mueller-Hinton agar. Zone sizes were interpreted according to CLSI 2012 guidelines. Out of 100 isolates, 85 were Acinetobacter baumannii, 9 were Acinetobacter johnsonii and 6 were Acinetobacter lwoffii. Eighty four isolates of A. baumannii, 8 isolates of A. johnsonii and all 6 isolates of A. lwoffii were multidrug resistant. One isolate from each of A. baumanni and A. johnsonii, and no isolate of A. lwoffii were susceptible to co-amoxiclav. Twenty eight isolates of A. baumanni, one isolate of A. johnsonii and no isolate of A. lwoffii were susceptible to ampicillin-sulbactam. Forty one (41) isolates of A. baumanni, one isolate of A. johnsonii and no isolate of A. lwoffii were susceptible to piperacillin-sulbactam. Eight isolates of A. baumanni, one isolate of A. johnsonii and no isolate of A. lwoffii were susceptible to piperacillin-tazobactam. Forty eight isolates of A. baumannii, one isolate of A. johnsonii, and no isolate of A. lwoffii were susceptible to cefoperazone-sulbactam. Cefoperazone-sulbactam was the most effective combination against 49% isolates of Acinetobacter. Ninety one percent isolates were resistant to piperacillin-tazobactam. Combinations having sulbactam were more effective as compared to others. This work also support the postulate that sulbactam, though not an antimicrobial, but does possess antibacterial activity against Acinetobacter species. Key words: Acinetobacter, β-lactam – β-lactamase inhibitor combinations, cefoperazone-sulbactam.
Highlights
Fu ull Length Research h Paper β-Lacttam - β-lactam β mase inhibit i tor com mbinattions a as the choice e thera apy forr multidrug rresista ant Acinetoba acter
Acinetobac cter, an imp portant noso ocomial path hogen, is c capable of c causing infe ectious outb breaks in critically ill patients wh hich results into high morbidity m and d mortality w worldwide
Twe enty eight isolates of A. baumann ni, one isola ate of A. joh hnsonii and no isolate o of A. lwoffiii were susce eptible to ampicillin-s sulbactam
Summary
Fu ull Length Research h Paper β-Lacttam - β-lactam β mase inhibit i tor com mbinattions a as the choice e thera apy forr multidrug rresista ant Acinetoba acter. The sittuation has become com mplicated due to the organism’s capability to o acquire diiverse resisttance mecha anisms. This s has resulte ed in the emergence of multidru ug resistant and pan-drrug resistantt strains. Acinetobac cter johnsoniii and 6 were e Acinetobac cter lwoffii. E ighty four isolates of A. baumannii, 8 isolates of A. johns sonii and alll 6 isolates of A. lwoffiii were multi drug resista ant. A lwoffii werre susceptib ble to co-amo oxiclav.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
